Landscapes / Targets
COVID-19
46 drugs act on COVID-19, in 52 active trials · Any stage · updated 20 Nov 2026
FollowEvery change as it happens, and a Monday email
Drugs46
| Drug | How it works | Company | Stage
Sources: FDA: the drug development process, ClinicalTrials.gov glossary | Next date
| Details |
|---|---|---|---|---|---|
— |
Sanofi · Public SNY |
On the market | 26 Nov 2026soonPhase 4 trial completes | ||
| Next date | 26 Nov 2026 · Phase 4 trial completes | ||||
| Open drug page | |||||
— |
Moderna · Public MRNA |
On the market | 11 Dec 2026soonPhase 4 trial completes | ||
| Next date | 11 Dec 2026 · Phase 4 trial completes | ||||
| Open drug page | |||||
— |
Moderna · Public MRNA |
On the market | 11 Dec 2026soonPhase 4 trial completes | ||
| Next date | 11 Dec 2026 · Phase 4 trial completes | ||||
| Open drug page | |||||
— |
BioNTech · Public BNTX |
On the market | 12 Apr 2027Phase 3 trial completes | ||
| Next date | 12 Apr 2027 · Phase 3 trial completes | ||||
| Open drug page | |||||
Ruconestnot checked |
— |
On the market | 31 Jul 2027Phase 4 trial completes | ||
| Next date | 31 Jul 2027 · Phase 4 trial completes | ||||
| Also tested for | Post-Viral Fatigue Syndrome, Post-Viral Disorder (Disorder) | ||||
| Open drug page | |||||
Ensitrelvirnot checked |
— |
Approved | — | ||
| Open drug page | |||||
Remdesivirnot checked |
SARS-CoV-2 nucleotide analog RNA polymerase inhibitor |
Gilead (Kite) · Public GILD |
Approved | — | |
| Open drug page | |||||
CCR5 co-receptor antagonist |
Phase 2/3 | 1 Dec 2026soonPhase 2/3 trial completes | |||
| Next date | 1 Dec 2026 · Phase 2/3 trial completes | ||||
| Also tested for | Long COVID | ||||
| Open drug page | |||||
— |
Phase 3 | 30 Jun 2027Phase 3 trial completes | |||
| Next date | 30 Jun 2027 · Phase 3 trial completes | ||||
| Also tested for | Long COVID, Post-COVID Syndrome and 1 more | ||||
| Open drug page | |||||
— |
Phase 3 | Jun 2027Phase 2 trial completes | |||
| Next date | Jun 2027 · Phase 2 trial completes | ||||
| Also tested for | Long COVID, COVID Long | ||||
| Open drug page | |||||
— |
Phase 3 | 31 Jul 2027Phase 3 trial completes | |||
| Next date | 31 Jul 2027 · Phase 3 trial completes | ||||
| Open drug page | |||||
— |
Pfizer · Public PFE |
Phase 3 | 28 Sep 2027Phase 3 trial completes | ||
| Next date | 28 Sep 2027 · Phase 3 trial completes | ||||
| Open drug page | |||||
— |
Phase 3 | 1 Sep 2028Phase 3 trial completes | |||
| Next date | 1 Sep 2028 · Phase 3 trial completes | ||||
| Also tested for | Parainfluenza | ||||
| Open drug page | |||||
— |
Merck & Co. · Public MRK |
Phase 3 | 26 Jan 2031Phase 3 trial completes | ||
| Next date | 26 Jan 2031 · Phase 3 trial completes | ||||
| Open drug page | |||||
— |
Phase 3 | — | |||
| Also tested for | Vaccines | ||||
| Open drug page | |||||
— |
Phase 2/3 | — | |||
| Open drug page | |||||
CoVLPnot checked |
— |
Phase 2/3 | — | ||
| Open drug page | |||||
— |
Pfizer · Public PFE |
Phase 3 | — | ||
| Open drug page | |||||
— |
Sinocelltech · Public 688520.SS |
Phase 2/3 | — | ||
| Open drug page | |||||
— |
Phase 2 | 31 Dec 2026Phase 2 trial completes | |||
| Next date | 31 Dec 2026 · Phase 2 trial completes | ||||
| Also tested for | Hematopoietic and Lymphoid System Neoplasm, Leukemia and 2 more | ||||
| Open drug page | |||||
No drugs match “”.
About this list
- Included
- Post-Acute COVID-19 Syndrome · Breakdown
- Covers
- 47 of 48 active trials the registry tags as COVID-19 (98%)
- Checked
- 40 of 46 drugs. The other 6 are marked “not checked” in the list. How we check
- Matches
- The mechanism of checked drugs, and drug names, so a drug not checked yet may be missing.
- Sources
- ClinicalTrials.gov updated 20 Nov 2026 · openFDA updated 20 Nov 2026